Replies to post #3 on Xeris Biopharma Holdings Inc (XERS)

[Golden Cross]

Xeris Pharmaceuticals (NASDAQ:XERS) Cut to "Hold" at Zacks Investment Research
6/23/20, 03:32 AM - Ticker Report
Summary
Zacks Investment Research lowered shares of Xeris Pharmaceuticals (NASDAQ:XERS) from a buy rating to a hold rating in a research report released on Saturday morning, Zacks.com reports. Zacks Investment Research currently has $5.75 target price on the stock. According to Zacks, Xeris ...